Dr. Guy Ungerechts

Clinician Scientist I

Dr. Guy Ungerechts MD, PhD is a medical oncologist focused on GI cancers with particular interests in translational medicine and early clinical trials of immuno(viro)therapy.

Ungerechts has been responsible for developing and conducting several Phase I/II and III trials with oncolytic viruses derived from different platforms, including oncolytic measles virus, vaccinia virus (JX-594), parvovirus H-1 and herpes simplex virus (HSV-1). His group recently demonstrated for the first time that the measles virus can be armed with immunomodulatory transgenes encoding for cytokines, immune checkpoint blockade antibodies and bispecific T-cell engager (BITEs) for enhanced immunovirotherapy.

Ungerechts also coordinates the German Virotherapy Consortium.

Current appointments

  • Clinician Scientist I, OICR;
  • Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute;
  • Head of the Research Group “Virotherapy”, Center for Cancer Therapeutics, Ottawa Hospital Research Institute (OHRI);
  • Attending Physician, Medical Oncology, The Ottawa Hospital;
  • Assistant Professor, Faculty of Medicine, University of Ottawa.

Research interests

  • Immunovirotherapy;
  • Recombinant oncolytic measles viruses;
  • Clinical trials;
  • Vaccina virus;
  • Parvovirus;
  • Herpes simplex.

Select publications

Ungerechts G, Bossow S, Leuchs B, Holm PS, Rommelaere J, Coffey M, Coffin R, Bell J, Nettelbeck DM.
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.
Mol Ther Methods Clin Dev. 2016 Apr 6;3:16018. doi: 10.1038/mtm.2016.18. eCollection 2016. Review.

Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W, Jaeger D, von Kalle C, Ungerechts G.
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
Mol Ther. 2014 Nov;22(11):1949-59. doi: 10.1038/mt.2014.160. Epub 2014 Aug 26.
PubMed PMID: 25156126 | PubMed Central PMCID: PMC4429737.

Ketzer P, Kaufmann JK, Engelhardt S, Bossow S, von Kalle C, Hartig JS, Ungerechts G, Nettelbeck DM.
Artificial riboswitches for gene expression and replication control of DNA and RNA viruses.
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):E554-62. doi: 10.1073/pnas.1318563111. Epub 2014 Jan 21.
PubMed PMID: 24449891 | PubMed Central PMCID: PMC3918795.

Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G.
Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
Hum Gene Ther. 2013 Jul;24(7):644-54. doi: 10.1089/hum.2012.205.
PubMed PMID: 23642239 | PubMed Central PMCID: PMC3719441.

Kaufmann JK, Bossow S, Grossardt C, Sawall S, Kupsch J, Erbs P, Hassel JC, von Kalle C, Enk AH, Nettelbeck DM, Ungerechts G.
Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
J Invest Dermatol. 2013 Apr;133(4):1034-42. doi:10.1038/jid.2012.459. Epub 2012 Dec 6.
PubMed PMID: 23223133.

Other scientific activities

  • Member of the American Society of Gene and Cell Therapy;
  • Member of the Editorial Board of Molecular Therapy – Oncolytics;
  • Member of the Editorial Board of Frontiers in Bioengineering and Biotechnology.


  •  Patent application filed on December 16, 2009, application number US 20110142811,
    Measles virus for the elimination of unwanted cell populations”.
  • Patent submitted, US provisional application US 61/944,353 (priority date February 25, 2014),
    Measles Virus for Immunovirotherapy of Cancer”.


  • 2016 Terry Fox New Investigator Award;
  • 2015 OICR Investigator Award;
  • 2013 German Cancer Aid, Max-Eder-Nachwuchsgruppenprogramm“, 2. period (Az. 110702);
  • 2009 German Cancer Aid, Max-Eder-Nachwuchsgruppenprogramm, 1. period (Az. 108307);
  • 2007 Research stipend of the DFG (German Research Foundation; UN 254 4-1);
  • 2005 Research stipend of the DFG (German Research Foundation; UN 254 1-1);
  • 2003 Stipend for postdocs of the IZKF (Interdisziplinäres Zentrum für Klinische Forschung);
  • 2003 Carl-Liebermeister-Award from the Medical Faculty, Eberhard-Karls-Universität Tübingen.

Previous experience and education

  • Assistant Professor, University of Ottawa;
  • Physician-Scientist OHRI;
  • Attending Physician Medical Oncology, Ottawa Hospital – General Campus;
    Advisory Boards AMGEN, AstraZeneca and Transgene;
  • Attending Physician National Center for Tumor Diseases, University Hospital Heidelberg, University of Heidelberg;
  • Physician National Center for Tumor Diseases, University Hospital Heidelberg, University Hospital (Germany);
  • Postdoctoral Research Fellow Oncolytic Viruses, Mayo Clinic;
  • Postdoctoral Research Fellow, Basic Research, Oncolytic Viruses, University Hospital Turbingen, University Hospital (Germany);
  • Research Fellow University Hospital Tuebingen, University Hospital (Germany).

Related links

Ottawa Hospital Research Institute – Dr. Guy Ungerechts

Opportunities to collaborate and contact

Dr. Ungerechts welcomes collaboration. Contact him at gungerechts@ohri.ca for more information.